Published:
Trading in Theravance Common Stock Halted
FDA Advisory Committee to Review Telavancin NDA
Theravance, Inc. (NASDAQ: THRX)
today announced that NASDAQ halted trading of Theravance common stock this
morning, November 19, 2008. The Anti-Infective Drugs Advisory Committee to
the U.S. Food and Drug Administration (FDA) meets today to review and
discuss the company's New Drug Application (NDA) for telavancin, a novel,
bactericidal, once-daily injectable investigational antibiotic for the
treatment of complicated skin and skin structure infections (cSSSI) caused
by Gram-positive bacteria, including resistant pathogens such as
methicillin-resistant Staphylococcus aureus (MRSA).
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. The company's key
programs include: telavancin for the treatment of serious Gram-positive
bacterial infections with Astellas Pharma Inc., the Horizon program and the
Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with
GlaxoSmithKline plc, and the Gastrointestinal Motility Dysfunction program.
By leveraging its proprietary insight of multivalency toward drug discovery
focused primarily on validated targets, Theravance is pursuing a next
generation strategy designed to discover superior medicines in areas of
significant unmet medical need. For more information, please visit the
company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE®
are registered trademarks of Theravance, Inc.
Copyright © 2009, MarketWire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,Pharmaceuticals and Biotech:Biotech, ,NASDAQ01,NASDAQ01,CA,SOUTH SAN FRANCISCO, CA
Search News
Daily News
